Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the United States Supplementary figure

This study was performed under a research contract between RTI International and Eli Lilly and Company and was funded by Eli Lilly and Company. LM Hess and NR Bhandari are employees of Eli Lilly and Company. AN Sireci is an employee of Loxo Oncology at Lilly, a wholly owned subsidiary of Eli Lilly and Company. JA Kaye and RC Parikh are employees of RTI Health Solutions. PM Krein is a former employee at Loxo Oncology at Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors would like to thank K Sharma fromEli Lilly Services India Pvt. Ltd. for providingmedical writing and editorial support.